.Attributes Medicine, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA permission after a bad trial, which highlights the numerous difficulties and also challenges of drug advancement in this particular setup.